Effect of drying and interfacial membrane composition on the antimicrobial activity of emulsified Citral (cas 5392-40-5)
-
Add time:07/15/2019 Source:sciencedirect.com
Citral-in-water emulsions were prepared with two different essential oil concentrations of 2.5 and 5.0% (w/w), then spray-dried in the presence of the same amount of maltodextrins (20%). The microcapsules were prepared with two different emulsifier compositions: monolayer microcapsules (ML) stabilized by sodium caseinate alone and layer-by-layer microcapsules (LBL) stabilized by sodium caseinate and pectin. The encapsulation efficiency was higher for LBL microcapsules (e.g. 99.6 ± 0.4% for 2.5% citral) than that for ML ones (e.g. 78.6 ± 0.6% for 2.5% citral) which confirm that the additional pectin layer was able to protect citral during the spray-drying process whatever citral concentration. Furthermore, our results showed that the antibacterial activity of the obtained microcapsules significantly depends on both citral concentration and interfacial membrane composition. The presence of two layers surrounding the citral droplets may result in a progressive and controlled release of the encapsulated citral.
We also recommend Trading Suppliers and Manufacturers of Citral (cas 5392-40-5). Pls Click Website Link as below: cas 5392-40-5 suppliers
Prev:Peanut allergens
Next:Antifungal activity and mechanism of Citral (cas 5392-40-5), limonene and eugenol against Zygosaccharomyces rouxii) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Vasorelaxant effect of the Lippia alba essential oil and its major constituent, Citral (cas 5392-40-5), on the contractility of isolated rat aorta07/22/2019
- Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models07/20/2019
- Preparation and characterization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles07/21/2019
- In vitro DNA binding studies of therapeutic and prophylactic drug Citral (cas 5392-40-5)07/19/2019
- Anti-inflammatory and anti-cancer activity of Citral (cas 5392-40-5): Optimization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®07/18/2019
- Physiological response of Saccharomyces cerevisiae to Citral (cas 5392-40-5) combined with thermal treatment07/17/2019
- Antifungal activity and mechanism of Citral (cas 5392-40-5), limonene and eugenol against Zygosaccharomyces rouxii07/16/2019